The World Health Organization's Global Initiative for Childhood Cancer was launched to decrease the disparities in childhood cancer outcomes and improve treatments for childhood cancer in resource-limited settings. Low-grade glioma, retinoblastoma, and Wilms tumors are among the index cancers included in this global initiative, as these cancers represent a large percentage of childhood tumors and are curable with cost-effective, evidence-based interventions. Herein, we discuss the global childhood tumor burden, the status of pediatric cancer surgery capacity and services around the world, and the strategic considerations for building pediatric surgical oncology capacity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00268-023-07010-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assisted Reproductive Technology and Risk of Childhood Cancer Among the Offspring of Parents With Infertility: Systematic Review and Meta-Analysis.
JMIR Cancer
March 2025
Department of Reproductive Medicine, Puer People's Hospital, 44 Zhenxing Avenue, Puer, Yunnan, 665000, China, 86 18082997667, 86 2121114.
Background: The relationship between assisted reproductive technology (ART) and childhood cancer risk has been widely debated. Previous meta-analyses did not adequately account for the impact of infertility, and this study addresses this gap.
Objective: Our primary objective was to assess the relative risk (RR) of childhood cancer in infertile populations using ART versus non-ART offspring, with a secondary focus on comparing frozen embryo transfer (FET) and fresh embryo transfer (fresh-ET).
Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.
Clin Cancer Res
March 2025
Hospital for Sick Children, Toronto, Ontario, Canada.
Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition condition characterized by a high lifetime risk for a wide spectrum of malignancies associated with germline pathogenic/likely pathogenic (P/LP) variants in the TP53 tumor suppressor gene. Secondary malignant neoplasms are particularly common. Early cancer detection through surveillance enables early intervention and leads to improved clinical outcomes with reduced tumor-related mortality and treatment-related morbidity.
View Article and Find Full Text PDFUnveiling the cancer epidemic in India: a glimpse into GLOBOCAN 2022 and past patterns.
Lancet Reg Health Southeast Asia
March 2025
Division of Implementation Research, Indian Council of Medical Research (ICMR), Headquarters, New Delhi, 110029, India.
Background: The Global Cancer Observatory (GLOBOCAN) 2022 estimates highlight cancer as a significant global health problem. In the South-East Asia-region, India ranks third in terms of cancer incidence, second for mortality, and 121 in terms of crude rates globally. As cancer risks increase with age, particularly affecting older individuals, this study explores the current cancer burden in India by analyzing the cancer landscape across different age groups, determining the population's risk of cancer diagnosis and death, and projecting the future cancer burden aligned with past mortality patterns.
View Article and Find Full Text PDFReassessing the role of the p.(Arg304Gln) missense AIP variant in pituitary tumorigenesis.
Eur J Endocrinol
March 2025
Centre for Endocrinology, Barts and The London School of Medicine, Queen Mary University of London, London, UK.
Objective: Heterozygous germline loss-of-function variants in AIP are associated with young-onset growth hormone and/or prolactin-secreting pituitary tumours. However, the pathogenic role of the c.911G>A; p.
View Article and Find Full Text PDFLocoregional Infusion of EGFR806-CAR T Cells for Recurrent or Refractory Pediatric CNS Tumors: Results of the Completed BrainChild02 Phase 1 Clinical Trial.
Neuro Oncol
March 2025
Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle Washington.
Background: Relapsed/refractory pediatric CNS tumors have a poor prognosis. EGFR is commonly overexpressed, but EGFRvIII mutations are uncommon. To target these tumors, we used chimeric antigen receptor (CAR) T cells with a binder based on mAb806 which recognizes ectopically expressed wild-type EGFR and EGFRvIII.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!